266 related articles for article (PubMed ID: 19852561)
21. Characterizing uncertainty and population variability in the toxicokinetics of trichloroethylene and metabolites in mice, rats, and humans using an updated database, physiologically based pharmacokinetic (PBPK) model, and Bayesian approach.
Chiu WA; Okino MS; Evans MV
Toxicol Appl Pharmacol; 2009 Nov; 241(1):36-60. PubMed ID: 19660485
[TBL] [Abstract][Full Text] [Related]
22. Physiologically based pharmacokinetic modeling of inhaled trichloroethylene and its oxidative metabolites in B6C3F1 mice.
Greenberg MS; Burton GA; Fisher JW
Toxicol Appl Pharmacol; 1999 Feb; 154(3):264-78. PubMed ID: 9931286
[TBL] [Abstract][Full Text] [Related]
23. Trichloroethylene and cancer: epidemiologic evidence.
Scott CS; Cogliano VJ
Environ Health Perspect; 2000 May; 108 Suppl 2():159-60. PubMed ID: 10807549
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of the dose-dependent kinetics of trichloroethylene: oral bolus dosing of rats.
Lee KM; Muralidhara S; White CA; Bruckner JV
Toxicol Appl Pharmacol; 2000 Apr; 164(1):55-64. PubMed ID: 10739744
[TBL] [Abstract][Full Text] [Related]
25. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland FA
Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
[TBL] [Abstract][Full Text] [Related]
26. Presystemic elimination of trichloroethylene in rats following environmentally relevant oral exposures.
Liu Y; Bartlett MG; White CA; Muralidhara S; Bruckner JV
Drug Metab Dispos; 2009 Oct; 37(10):1994-8. PubMed ID: 19581386
[TBL] [Abstract][Full Text] [Related]
27. Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice.
Marino DJ; Clewell HJ; Gentry PR; Covington TR; Hack CE; David RM; Morgott DA
Regul Toxicol Pharmacol; 2006 Jun; 45(1):44-54. PubMed ID: 16442684
[TBL] [Abstract][Full Text] [Related]
28. Risk assessment of arsenic-induced internal cancer at long-term low dose exposure.
Liao CM; Shen HH; Chen CL; Hsu LI; Lin TL; Chen SC; Chen CJ
J Hazard Mater; 2009 Jun; 165(1-3):652-63. PubMed ID: 19062162
[TBL] [Abstract][Full Text] [Related]
29. Trichloroethylene, trichloroacetic acid, and dichloroacetic acid: do they affect eye development in the Sprague-Dawley rat?
Warren DA; Graeter LJ; Channel SR; Eggers JS; Goodyear CD; Macmahon KL; Sudberry GL; Latendresse JR; Fisher JW; Baker WH
Int J Toxicol; 2006; 25(4):279-84. PubMed ID: 16815816
[TBL] [Abstract][Full Text] [Related]
30. Trichloroethylene: mechanisms of renal toxicity and renal cancer and relevance to risk assessment.
Lock EA; Reed CJ
Toxicol Sci; 2006 Jun; 91(2):313-31. PubMed ID: 16421178
[TBL] [Abstract][Full Text] [Related]
31. Approaches for applications of physiologically based pharmacokinetic models in risk assessment.
Thompson CM; Sonawane B; Barton HA; DeWoskin RS; Lipscomb JC; Schlosser P; Chiu WA; Krishnan K
J Toxicol Environ Health B Crit Rev; 2008 Aug; 11(7):519-47. PubMed ID: 18584453
[TBL] [Abstract][Full Text] [Related]
32. Issues in the pharmacokinetics of trichloroethylene and its metabolites.
Chiu WA; Okino MS; Lipscomb JC; Evans MV
Environ Health Perspect; 2006 Sep; 114(9):1450-6. PubMed ID: 16966104
[TBL] [Abstract][Full Text] [Related]
33. Trichloroethylene-contaminated drinking water and congenital heart defects: a critical analysis of the literature.
Watson RE; Jacobson CF; Williams AL; Howard WB; DeSesso JM
Reprod Toxicol; 2006 Feb; 21(2):117-47. PubMed ID: 16181768
[TBL] [Abstract][Full Text] [Related]
34. Metabolism, toxicity, and carcinogenicity of trichloroethylene.
Bruckner JV; Davis BD; Blancato JN
Crit Rev Toxicol; 1989; 20(1):31-50. PubMed ID: 2673291
[TBL] [Abstract][Full Text] [Related]
35. Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.
Clewell HJ; Gentry PR; Gearhart JM
J Toxicol Environ Health; 1997 Dec; 52(6):475-515. PubMed ID: 9397182
[TBL] [Abstract][Full Text] [Related]
36. Physiologically-based pharmacokinetic and toxicokinetic models in cancer risk assessment.
Krishnan K; Johanson G
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2005; 23(1):31-53. PubMed ID: 16291521
[TBL] [Abstract][Full Text] [Related]
37. Trichloroethylene. II. Mechanism of carcinogenicity of trichloroethylene.
Motohashi N; Nagashima H; Molnár J
In Vivo; 1999; 13(3):215-9. PubMed ID: 10459494
[TBL] [Abstract][Full Text] [Related]
38. Reducing uncertainty in risk assessment by using specific knowledge to replace default options.
McClellan RO
Drug Metab Rev; 1996; 28(1-2):149-79. PubMed ID: 8744594
[TBL] [Abstract][Full Text] [Related]
39. Initial uptake kinetics in human skin exposed to dilute aqueous trichloroethylene in vitro.
Bogen KT; Keating GA; Meissner S; Vogel JS
J Expo Anal Environ Epidemiol; 1998; 8(2):253-71. PubMed ID: 9577754
[TBL] [Abstract][Full Text] [Related]
40. Contribution of direct solvent injury to the dose-dependent kinetics of trichloroethylene: portal vein administration to rats.
Lee KM; Muralidhara S; Schnellmann RG; Bruckner JV
Toxicol Appl Pharmacol; 2000 Apr; 164(1):46-54. PubMed ID: 10739743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
